The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

 
Web www.patentalert.com

< VPR mutant protein and its encoding gene having apoptosis-inducing action

< Glycoconjugates including more than one peptide

> ETS-related gene overexpressed in human breast and epithelial cancers

> 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors

~ 00298